Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pfs230D1-EPA/Matrix-M Vaccine in Adults in Mali
NCT05135273Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2021
- Primary completion
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Pfs230D1-EPA + Matrix-M in Plasmodium falciparum malaria (8 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Local and Systemic Adverse Events at 14 months and Number of Local and Systemic Serious Adverse Events at 14 months. Started Oct 2021; status: completed.
02
Drugs
Pfs230D1-EPA + Matrix-M
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT05135273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135273.